Friday, 16 October 2026European Markets

PROSAFE Stock Bullish By 9% So Far On Thursday

Loading stream...

(VIANEWS) - Shares of PROSAFE (Oslo Børs Benchmark Index_GI: PRS.OL) rose 9.06% to kr127.60 at 11:37 EST on Thursday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 0.74% to kr1,212.88, following the last session's upward trend. This seems, up until now, a somewhat positive trend trading session today.

PROSAFE's last close was kr117.00, 56.51% below its 52-week high of kr269.00.

About PROSAFE

Prosafe SE, together with its subsidiaries, owns and operates semi-submersible accommodation vessels in Brazil, Norway, Trinidad and Tobago, and the United Kingdom. It is also involved in the maintenance and modification of installations on fields for the production, hook-up and commissioning of new fields, tiebacks to existing infrastructure, and decommissioning activities. The company owns and operates a fleet of six semi-submersible accommodation vessels and one tender support vessel. It primarily serves oil and gas industries. The company was founded in 1972 and is headquartered in Stavanger, Norway.

Earnings Per Share

As for profitability, PROSAFE has a trailing twelve months EPS of kr1.74.

PE Ratio

PROSAFE has a trailing twelve months price to earnings ratio of 73.33. Meaning, the purchaser of the share is investing kr73.33 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.08%.

More news about PROSAFE (PRS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com